Department of Neurosurgery, University of Illinois at Chicago, 912 S. Wood Street, 4N NPI, Chicago, IL, 60612, USA.
J Neurooncol. 2018 Apr;137(2):223-231. doi: 10.1007/s11060-018-2747-2. Epub 2018 Jan 11.
Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future.
系统递送抗血管生成药物在改善原发性和复发性脑胶质瘤患者的总体生存率方面效果不佳，部分原因是剂量限制毒性。随着新的、有效的局部递送方法和载体的发展，否则会产生致死剂量的抗血管生成化疗药物可用于治疗肿瘤，同时最大限度地减少全身副作用。目前的体外和体内动物研究已经显示出有希望的结果，鼓励在不久的将来进行局部抗血管生成治疗的人体临床试验。
